Cancer52 releases an analysis on rare and less common cancer research spend
In 2022, Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less...
A joint statement on the voluntary scheme for branded medicines pricing and access (VPAS)
Patient charities set out a shared vision for the next VPAS scheme. Cancer52 have joined forces with the Charity Medicines Access...
Cancer52 Annual Review 2021-2022
We are incredibly pleased to present our Annual Review for the financial year 2021-2022. It covers the period following the COVID-19...